Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.50USD
12:20pm EDT
Change (% chg)

$0.00 (+0.02%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.55
Day's Low
$0.50
Volume
170,597
Avg. Vol
187,617
52-wk High
$2.13
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Cytori announces corporate restructuring & cost reduction plan
Friday, 1 Sep 2017 04:15pm EDT 

Sept 1 (Reuters) - Cytori Therapeutics Inc :Cytori announces corporate restructuring & cost reduction plan.Cytori announces corporate restructuring & cost reduction plan.Cytori Therapeutics Inc - ‍restructuring is expected to reduce Cytori's workforce by approximately 50% and significantly reduce quarterly operational cash burn​.Cytori Therapeutics - habeo program for scleroderma is expected to move forward based on feedback from forthcoming meetings with FDA in U.S., PMDA in Japan​.Cytori Therapeutics Inc - ‍company and its advisors, tap advisors, will consider a range of options including a sale of company and a reverse merger​.Cytori Therapeutics Inc - ‍announced a substantial corporate restructuring intended to significantly reduce expenses​.Cytori Therapeutics Inc says ‍have engaged tap advisors to "help us evaluate several potential opportunities company has​".Cytori Therapeutics - ‍restructuring while maintaining ability to execute on its BARDA-sponsored cell therapy program, japanese business, oncology program​.  Full Article

Cytori Therapeutics Q2 loss per share $0.19
Thursday, 10 Aug 2017 04:25pm EDT 

Aug 10 (Reuters) - Cytori Therapeutics Inc :Cytori reports second quarter 2017 business and financial results.Q2 loss per share $0.19.Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Cytori Therapeutics Inc - expects full year 2017 operating cash burn to be higher than 2016.Says Q2 2017 total revenues were $1.5 million compared to $2.8 million for same periods in 2016.Cytori Therapeutics Inc - full year 2017 updated operating cash burn forecasted to be within a range of $20 million to $23 million.  Full Article

Cytori announces top-line 24- and 48-week results
Monday, 24 Jul 2017 08:00am EDT 

July 24 (Reuters) - Cytori Therapeutics Inc ::Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma.Cytori Therapeutics Inc - ‍clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup​.Cytori Therapeutics Inc - statistical significance not achieved in primary or secondary efficacy endpoints.Cytori Therapeutics Inc - intends to submit full star data set to American College Of Rheumatology meeting in November 3-8, 201.  Full Article

Cytori and Barda execute $13.4 mln contract option for burn clinical trial
Wednesday, 31 May 2017 09:00am EDT 

May 31 (Reuters) - Cytori Therapeutics Inc :Cytori and Barda execute $13.4 million contract option for burn clinical trial.Cytori - Executed option will fund relief trial, U.S. pilot clinical trial of Cytori Cell Therapy (DCCT-10) in thermal burn injury.  Full Article

Cytori and Barda execute $13.4 mln contract option for burn clinical trial
Wednesday, 31 May 2017 09:00am EDT 

May 31 (Reuters) - Cytori Therapeutics Inc :Cytori and Barda execute $13.4 million contract option for burn clinical trial.Cytori - executed option will fund the company’s relief trial, a U.S. Pilot clinical trial of Cytori cell therapy (dcct-10) in thermal burn injury.Cytori - trial is approved to enroll up to 30 patients in up to 10 U.S. Sites with study initiation expected to occur in Q4 2017.  Full Article

Cytori Therapeutics files for mixed shelf of up to $100 mln
Friday, 12 May 2017 05:32pm EDT 

May 12 (Reuters) - Cytori Therapeutics Inc ::Files for mixed shelf of up to $100.0 million - SEC filing.  Full Article

Cytori Q1 adjusted loss per share $0.26 excluding items
Thursday, 11 May 2017 04:25pm EDT 

May 11 (Reuters) - Cytori Therapeutics Inc ::Cytori reports first quarter 2017 business and financial results.Q1 adjusted loss per share $0.26 excluding items.Q1 GAAP loss per share $0.33.Q1 revenue $1.6 million versus $2.9 million.Q1 revenue view $2.6 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Says expects full year 2017 operating cash burn to be higher than 2016.Cytori therapeutics inc - 2017 financial guidance reiterated.  Full Article

Cytori says public offering of 8.60 mln common shares priced at $1.10 per share
Tuesday, 11 Apr 2017 08:45am EDT 

Cytori Therapeutics Inc : Cytori announces pricing of $9.5m public offering of common stock .Says public offering of 8.60 million common shares priced at $1.10per share.  Full Article

Cytori reports proposed public offering of common stock
Monday, 10 Apr 2017 04:01pm EDT 

Cytori Therapeutics Inc : Cytori announces proposed public offering of common stock .Cytori Therapeutics -intends to use net proceeds for working capital and general corporate purposes, including funding of habeo,ati-0918 development programs.  Full Article

Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract
Monday, 10 Apr 2017 07:00am EDT 

Cytori Therapeutics Inc - :Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract.  Full Article

BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement

* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing